Report
Kelsey Tsai
EUR 100.00 For Business Accounts Only

Icon's operational discipline should drive earnings growth as its scale expands.

Icon’s healthy fourth-quarter performance was driven by demand across biotech and large pharma. We are marginally increasing our fair value estimate to $105 per share from $104 to reflect the time value of money. The company’s 2018 revenue and earnings per share guidance--$2.52 billion-$2.64 billion and $5.89-$6.09, respectively--incorporates the new revenue recognition accounting standard ASC 606. Our 2018 estimates fall toward the midpoint of management’s expectations. We believe the firm’s gl...
Underlying
ICON Plc

Icon is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. Co. specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. Co.'s services, which are integral elements of the clinical development process, include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. Co. in engaged in conducting clinical trials in most therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kelsey Tsai

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch